TrialJournal of neuro-oncology2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
J Duerinck et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this paperpooled ittrialcites it